• 1
    United Network for Organ Sharing. Available at
  • 2
    Anand AC, Hubscher SG, Gunson BK, McMaster P, Neuberger JM. Timing, significance, and prognosis of late acute liver allograft rejection. Transplantation 1995; 60: 10981103.
  • 3
    Soin AS, Rasmussen A, Jamieson NV et al. CsA levels in the early posttransplant period—Predictive of chronic rejection in liver transplantation? Transplantation 1995; 59: 11191123.
  • 4
    Demetris AJ, Ruppert K, Dvorchik I et al. Real-time monitoring of acute liver-allograft rejection using the Banff schema. Transplantation 2002; 74: 12901296.
  • 5
    Ramji A, Yoshida EM, Bain VG et al. Late acute rejection after liver transplantation: The western Canada experience. Liver Transpl 2002; 8: 945951.
  • 6
    Mor E, Gonwa TA, Husberg BS, Goldstein RM, Klintmalm GB. Late-onset acute rejection in orthotopic liver transplantation-associated risk factors and outcome. Transplantation 1992; 54: 821824.
  • 7
    Klintmalm GB, Nery JR, Husberg BS, Gonwa TA, Tillery GW. Rejection in liver transplantation. Hepatology 1989; 10: 978985.
  • 8
    Wiesner R, Rabkin J, Klintmalm G et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001; 7: 442450.
  • 9
    Wiesner RH, Shorr JS, Steffen BJ, Chu AH, Gordon RD, Lake JR. Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C. Liver Transpl 2005; 11: 750759.
  • 10
    Lake JR, Shorr JS, Steffen BJ, Chu AH, Gordon RD, Wiesner RH. Differential effects of donor age in liver transplant recipients infected with hepatitis B, hepatitis C, and without viral hepatitis. Am J Transplant 2005; 5: 549557.
  • 11
    Kaufman DB, Shapiro R, Lucey MR, Cherikh WS, Bustami RT, Dyke DB. Immunosuppression: Practice and trends. Am J Transplant 2004; 4: 3853.
  • 12
    Wiesner RH. A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: A report of the United States FK506 Study Group. Transplantation 1998; 66: 493499.
  • 13
    Charleton M, Seaberg E, Wiesner R et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28: 823830.
  • 14
    Sheiner PA, Schwartz ME, Mor E et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995; 21: 3034.
  • 15
    Gane EJ, Portmann BC, Naomoumov NV et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334: 815820.
  • 16
    Prieto M, Berenguer M, Rayon JM et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following liver transplantation: Relationship with rejection episodes. Hepatology 1999; 29: 250256.
  • 17
    Dickinson DM, Ellison MD, Webb RL. AJTS—Data sources and structure. Am J Transplant 2003; 3 (Suppl 4): 1328.
  • 18
    Wolfe RA, Webb RL, Dickinson DM et al. Analytical approaches for transplant research. Am J Transplant 2003; 3 (Suppl 4): 103113.